Literature DB >> 18367041

Statin myopathy.

Kristofer A Radcliffe1, William W Campbell.   

Abstract

Many different classes of medications can cause toxic myopathy. One of the most frequently implicated classes is the statins. Statin myotoxicity ranges from asymptomatic creatine kinase elevations or myalgias to muscle necrosis and fatal rhabdomyolysis. Statins may also cause an autoimmune myopathy requiring immunosuppressive treatment. The mechanisms of statin myotoxicity are unclear. If unrecognized in its early manifestations, complications from continued statin therapy may lead to rhabdomyolysis and death. Risk factors for myotoxicity include concomitant medication use and medical conditions, and the patient's underlying genetic constitution. We review these considerations along with the recommended evaluation and treatment for patients presenting with statin myotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367041     DOI: 10.1007/s11910-008-0011-4

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  45 in total

1.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  Stroke       Date:  2002-09       Impact factor: 7.914

Review 2.  Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?

Authors:  David W J Clark; Johanna Strandell
Journal:  Eur J Clin Pharmacol       Date:  2006-04-22       Impact factor: 2.953

3.  HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism.

Authors:  Kotaro Tokinaga; Toru Oeda; Yoshifumi Suzuki; Yasuhisa Matsushima
Journal:  Endocr J       Date:  2006-05-25       Impact factor: 2.349

4.  Muscle symptoms associated with statins: a series of twenty patients.

Authors:  Kari Soininen; Mikko Niemi; Esa Kilkki; Timo Strandberg; Kari T Kivistö
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-01       Impact factor: 4.080

5.  Myopathy associated with atorvastatin-ezetimibe combination therapy.

Authors:  Linda A Weffald; Lynn A Flach
Journal:  Pharmacotherapy       Date:  2007-02       Impact factor: 4.705

6.  Striated muscle safety of ezetimibe/simvastatin (Vytorin).

Authors:  Michael H Davidson; Darbie Maccubbin; Michael Stepanavage; John Strony; Thomas Musliner
Journal:  Am J Cardiol       Date:  2005-11-21       Impact factor: 2.778

Review 7.  Clinical perspectives of statin-induced rhabdomyolysis.

Authors:  Kenneth A Antons; Craig D Williams; Steven K Baker; Paul S Phillips
Journal:  Am J Med       Date:  2006-05       Impact factor: 4.965

8.  [Polymyositis induced or associated with lipid-lowering drugs: five cases].

Authors:  A-L Fauchais; J Iba Ba; P Maurage; X Kyndt; D Bataille; E Hachulla; D Parent; V Queyrel; M Lambert; U Michon Pasturel; P-Y Hatron; P Vanhille; B Devulder
Journal:  Rev Med Interne       Date:  2004-04       Impact factor: 0.728

9.  Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Authors:  Chantale Simard; Paul Poirier
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 10.  Primary evaluation and management of statin therapy complications.

Authors:  Dean A Seehusen; Chad A Asplund; Dawn R Johnson; Kevin A Horde
Journal:  South Med J       Date:  2006-03       Impact factor: 0.954

View more
  5 in total

Review 1.  Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2013-11       Impact factor: 3.275

2.  Curcumin improves atorvastatin-induced myotoxicity in rats: Histopathological and biochemical evidence.

Authors:  Said Said Elshama; Ayman El-Meghawry El-Kenawy; Hosam-Eldin Hussein Osman
Journal:  Int J Immunopathol Pharmacol       Date:  2016-08-09       Impact factor: 3.219

3.  Stepwise approach to myopathy in systemic disease.

Authors:  Jasvinder Chawla
Journal:  Front Neurol       Date:  2011-08-05       Impact factor: 4.003

4.  Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.

Authors:  Sudarshini Ramanathan; Daman Langguth; Todd A Hardy; Nidhi Garg; Chris Bundell; Arada Rojana-Udomsart; Russell C Dale; Thomas Robertson; Andrew L Mammen; Stephen W Reddel
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-04-02

5.  Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury.

Authors:  Mohammed Abdulrazaq; Farqad Hamdan; Waseem Al-Tameemi
Journal:  Iran J Basic Med Sci       Date:  2015-08       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.